@article{0d2be859bedd467faa783d60d0c8e090,
title = "Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia",
author = "Mulligan, {Stephen P.} and Stephen Opat and Paula Marlton and Bryone Kuss and Poppy Gerungan and Andrea Puig and Marija McGeachie and Tam, {Constantine S.}",
note = "Funding Information: The study was sponsored by Janssen‐Cilag Pty Ltd Australia. Janssen Biotech, Inc. co‐develops and co ‐commercialises ibrutinib in collaboration with Pharmacyclics, Inc. Janssen‐Cilag Pty Ltd Australia contracted Prospection Pty Ltd to perform the analysis. Funding Information: SM notes honoraria/advisory or speaker services from Janssen, Abbvie, and AstraZeneca. SO notes consultancy for AbbVie, AstraZeneca, Janssen and Roche, research funding from AbbVie, AstraZenca, BeiGene, Gilead, Janssen, Pharmacyclics, Roche, Sandoz and Takeda, and honoraria from AbbVie, AstraZeneca, Celgene, CSL Behring, Gilead, Janssen, Merck, Roche, and Takeda. PM notes paid advisory/ consulting or speaker services for AbbVie, Astellas, BeiGene, Gilead, Janssen, Novartis, Pfizer, and Roche. BK notes honoraria, consultancy, and advisory boards from Roche, AbbVie, Janssen, Mundipharma, Takeda, Gilead, Merck, CSL, Pharamacyclics, and AstraZeneca, speaker fees from Gilead, Janssen, Roche, AbbVie and AstraZeneca, and conference registration from AbbVie, Roche, and AstraZeneca. AM, MM and PG are employees of Janssen‐Cilag Pty Ltd Australia. CT received honoraria from Janssen, AbbVie, BeiGene, Novartis, LOXO and research funding from Janssen, AbbVie, and BeiGene. ",
year = "2022",
month = aug,
doi = "10.1111/bjh.18306",
language = "English",
volume = "198",
pages = "790--793",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",
}